IceCure Medical Ltd. (NASDAQ: ICCM) is a company specializing in cryoablation technology, which is a minimally-invasive method to destroy tumors by freezing them. The company is preparing to release its quarterly earnings on November 19, 2025. Wall Street anticipates an earnings per share (EPS) of -$0.05 and revenue of approximately $714,000 for this period.
ICCM's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -2.67, indicating negative earnings. This is further supported by a negative earnings yield of -37.46%, highlighting ongoing financial difficulties. Despite these challenges, ICCM's price-to-sales ratio is 17.53, showing that investors are willing to pay $17.53 for every dollar of sales.
The enterprise value to sales ratio is 16.45, slightly lower than the price-to-sales ratio. This reflects the company's valuation, including its debt. The enterprise value to operating cash flow ratio is -3.23, indicating difficulties in generating positive cash flow from operations. These figures suggest that ICCM is facing challenges in achieving profitability.
ICCM's debt-to-equity ratio is 0.82, which shows a moderate level of debt compared to its equity. This suggests that the company is not overly reliant on debt for financing. Additionally, the current ratio of 1.18 indicates that ICCM has a reasonable level of liquidity to cover its short-term liabilities, providing some financial stability amidst its challenges.
